Bilateral visual outcomes and service utilization of patients treated for 3 years with ranibizumab for neovascular age-related macular degeneration

Bilateral visual outcomes and service utilization of patients treated for 3 years with ranibizumab for neovascular age-related macular degeneration

Randhir Chavan,1,* Swati Panneerselvam,1,* Parul Adhana,1 Nirodhini Narendran,1 Yit Yang1,2 1Eye Infirmary, New Cross Hospital, Royal Wolverhampton Hospitals NHS Trust Wolverhampton, West Midlands, UK; 2Faculty of Life and Health Sciences, Aston University, Birmingham, UK *These authors...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Chavan R, Panneerselvam S, Adhana P, Narendran N, Yang Y
Formato: article
Lenguaje:EN
Publicado: Dove Medical Press 2014
Materias:
Ophthalmology
RE1-994
Acceso en línea:https://doaj.org/article/095703c8e3c849199eceb865a298a8fa
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
id oai:doaj.org-article:095703c8e3c849199eceb865a298a8fa
record_format dspace
spelling oai:doaj.org-article:095703c8e3c849199eceb865a298a8fa2021-12-02T04:29:24ZBilateral visual outcomes and service utilization of patients treated for 3 years with ranibizumab for neovascular age-related macular degeneration1177-5483https://doaj.org/article/095703c8e3c849199eceb865a298a8fa2014-04-01T00:00:00Zhttp://www.dovepress.com/bilateral-visual-outcomes-and-service-utilization-of-patients-treated--a16382https://doaj.org/toc/1177-5483 Randhir Chavan,1,* Swati Panneerselvam,1,* Parul Adhana,1 Nirodhini Narendran,1 Yit Yang1,2 1Eye Infirmary, New Cross Hospital, Royal Wolverhampton Hospitals NHS Trust Wolverhampton, West Midlands, UK; 2Faculty of Life and Health Sciences, Aston University, Birmingham, UK *These authors contributed equally to this paper Background: The aim of this study was to describe bilateral visual outcomes and the effect of incomplete follow-up after 3 years of ranibizumab therapy for neovascular age-related macular degeneration. Secondarily, the demands on service provision over a 3-year period were described. Methods: Data on visual acuity, hospital visits, and injections were collected over 36 months on consecutive patients commencing treatment over a 9-month period. Visual outcome was determined for 1) all patients, using last observation carried forward for missed visits due to early discontinuation and 2) only those patients completing full 36-month follow-up. Results: Over 3 years, 120 patients cumulatively attended hospital for 1,823 noninjection visits and 1,365 injection visits. A visual acuity loss of <15 letters (L) was experienced by 78.2% of patients. For all patients (n=120), there was a mean loss of 1.68 L using last observation carried forward for missing values. Excluding five patients who died and 30 who discontinued follow-up, mean gain was 1.47 L. In bilateral cases, final acuity was on average 9 L better in second eyes compared to first eyes. Also, 91% of better-seeing eyes continued to be the better-seeing eye. Conclusion: We have demonstrated our approach to describing the long-term service provision and visual outcomes of ranibizumab therapy for neovascular age-related macular degeneration in a consecutive cohort of patients. Although there was a heavy burden with very frequent injections and clinic visits, patients can expect a good level of visual stability and a very high chance of maintaining their better-seeing eye for up to 3 years. Keywords: visual acuity, real-world data, long term follow up, lucentisChavan RPanneerselvam SAdhana PNarendran NYang YDove Medical PressarticleOphthalmologyRE1-994ENClinical Ophthalmology, Vol 2014, Iss default, Pp 717-723 (2014)
institution DOAJ
collection DOAJ
language EN
topic Ophthalmology
RE1-994
spellingShingle Ophthalmology
RE1-994
Chavan R
Panneerselvam S
Adhana P
Narendran N
Yang Y
Bilateral visual outcomes and service utilization of patients treated for 3 years with ranibizumab for neovascular age-related macular degeneration
description Randhir Chavan,1,* Swati Panneerselvam,1,* Parul Adhana,1 Nirodhini Narendran,1 Yit Yang1,2 1Eye Infirmary, New Cross Hospital, Royal Wolverhampton Hospitals NHS Trust Wolverhampton, West Midlands, UK; 2Faculty of Life and Health Sciences, Aston University, Birmingham, UK *These authors contributed equally to this paper Background: The aim of this study was to describe bilateral visual outcomes and the effect of incomplete follow-up after 3 years of ranibizumab therapy for neovascular age-related macular degeneration. Secondarily, the demands on service provision over a 3-year period were described. Methods: Data on visual acuity, hospital visits, and injections were collected over 36 months on consecutive patients commencing treatment over a 9-month period. Visual outcome was determined for 1) all patients, using last observation carried forward for missed visits due to early discontinuation and 2) only those patients completing full 36-month follow-up. Results: Over 3 years, 120 patients cumulatively attended hospital for 1,823 noninjection visits and 1,365 injection visits. A visual acuity loss of <15 letters (L) was experienced by 78.2% of patients. For all patients (n=120), there was a mean loss of 1.68 L using last observation carried forward for missing values. Excluding five patients who died and 30 who discontinued follow-up, mean gain was 1.47 L. In bilateral cases, final acuity was on average 9 L better in second eyes compared to first eyes. Also, 91% of better-seeing eyes continued to be the better-seeing eye. Conclusion: We have demonstrated our approach to describing the long-term service provision and visual outcomes of ranibizumab therapy for neovascular age-related macular degeneration in a consecutive cohort of patients. Although there was a heavy burden with very frequent injections and clinic visits, patients can expect a good level of visual stability and a very high chance of maintaining their better-seeing eye for up to 3 years. Keywords: visual acuity, real-world data, long term follow up, lucentis
format article
author Chavan R
Panneerselvam S
Adhana P
Narendran N
Yang Y
author_facet Chavan R
Panneerselvam S
Adhana P
Narendran N
Yang Y
author_sort Chavan R
title Bilateral visual outcomes and service utilization of patients treated for 3 years with ranibizumab for neovascular age-related macular degeneration
title_short Bilateral visual outcomes and service utilization of patients treated for 3 years with ranibizumab for neovascular age-related macular degeneration
title_full Bilateral visual outcomes and service utilization of patients treated for 3 years with ranibizumab for neovascular age-related macular degeneration
title_fullStr Bilateral visual outcomes and service utilization of patients treated for 3 years with ranibizumab for neovascular age-related macular degeneration
title_full_unstemmed Bilateral visual outcomes and service utilization of patients treated for 3 years with ranibizumab for neovascular age-related macular degeneration
title_sort bilateral visual outcomes and service utilization of patients treated for 3 years with ranibizumab for neovascular age-related macular degeneration
publisher Dove Medical Press
publishDate 2014
url https://doaj.org/article/095703c8e3c849199eceb865a298a8fa
work_keys_str_mv AT chavanr bilateralvisualoutcomesandserviceutilizationofpatientstreatedfornbsp3nbspyearswithranibizumabforneovascularagerelatedmaculardegeneration
AT panneerselvams bilateralvisualoutcomesandserviceutilizationofpatientstreatedfornbsp3nbspyearswithranibizumabforneovascularagerelatedmaculardegeneration
AT adhanap bilateralvisualoutcomesandserviceutilizationofpatientstreatedfornbsp3nbspyearswithranibizumabforneovascularagerelatedmaculardegeneration
AT narendrann bilateralvisualoutcomesandserviceutilizationofpatientstreatedfornbsp3nbspyearswithranibizumabforneovascularagerelatedmaculardegeneration
AT yangy bilateralvisualoutcomesandserviceutilizationofpatientstreatedfornbsp3nbspyearswithranibizumabforneovascularagerelatedmaculardegeneration
_version_ 1718401168879648768

Ejemplares similares